Rocky Mountain Cannabis Research Center

落基山大麻研究中心

• 批准号: 10709326
• 负责人: KENT E. HUTCHISON
• 金额: $ 277.36万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-01 至 2028-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10709326
• 关键词: Acute; Adolescence; Adult; Affect; Behavior; Behavioral; Biological; Biological Assay; Biological Markers; Blood; Blood specimen; Cannabidiol; Cannabinoids; Cannabis; Centers of Research Excellence; Communities; Data; Data Analyses; Data Collection; Data Set; District of Columbia; Dose; Elderly; Endocannabinoids; Epidiolex; Foundations; Funding; Future; Goals; Health; Hemp; Industry; Knowledge; Laboratories; Legal; Legal Status; Lipids; Longevity; Machine Learning; Measures; Mediating; Medical Marijuana; Modeling; Moods; Neurocognition; Neurocognitive; North America; Outcome; Participant; Pharmacologic Substance; Pharmacology; Pharmacy facility; Pilot Projects; Placebos; Public Health; Randomized; Recreation; Research; Research Project Grants; Resources; Risk; Sampling; Scientist; Self Administration; Structure; System; Terpenes; Tetrahydrocannabinol; Time; United States; United States National Institutes of Health; age group; behavior measurement; behavioral outcome; data cleaning; data harmonization; data sharing; design; emerging adult; endogenous cannabinoid system; experience; innovation; lipid mediator; middle age; novel; repository; response; success; user-friendly; web based interface

PROJECT SUMMARY/ABSTRACT ROCKY MOUNTAIN CANNABIS RESEARCH CENTER (RM-CRC) The United States has recently experienced enormous changes in the legal status and public acceptance of cannabis. Recreational and medical cannabis products that contain varying amounts of tetrahydrocannabinol (THC) and cannabidiol (CBD) are now widely available throughout North America. Despite these changes, research on the effects of THC and CBD has been lacking. The central goals of this Research Center of Excellence application are to evaluate, in three research projects that span emerging, middle-aged, and older adults, how CBD affects the use of and subjective response to THC, and whether these effects are mediated by the endocannabinoid system (ECS) and associated lipids. To that end, the three research projects within the RM-CRC utilize research strategies that capitalize on three key innovations. First, the projects will employ mobile pharmacology laboratories to collect biological samples and assess the acute effects of THC and CBD on key neurocognitive and behavioral outcomes, endocannabinoids, and other lipids that interact with the ECS. Second, under the auspices of an FDA IND we hold for hemp-derived CBD, projects will randomly assign participants to CBD or placebo and will parametrically manipulate either the dose of CBD or whether the CBD product contains THC, to determine how hemp-derived CBD products may impact the effects of THC. Finally, the projects rely on newly designed assays within our Cannabis Research Analytics Core (CRAC) to measure cannabinoids, metabolites, terpenes, endocannabinoids, and other lipid mediators in blood samples. The Data Harmonization and Analysis Core (DHAC) will deploy a single-solution system to support data collection, harmonization across projects, and sharing of the data with the larger scientific community directly and via NIH approved repositories. The DHAC will also harmonize previously collected data (from 7 R01s, n=1359) and conduct advanced machine learning analyses of the relationships between THC and CBD blood levels, endocannabinoids and other lipid mediators, and behavioral data. The results will inform center-wide analyses of the harmonized P50 project data. Thus, the CRAC and DHAC provide the RM-CRC with significant added value that will allow the Center to generate significant new knowledge with respect to how changes in the ECS and related lipids mediate the effects of THC and CBD across the lifespan. The RM-CRC is expected to be a significant resource to the field more broadly by providing other scientists access to data regarding CBD effects on psychiatric and health outcomes, cannabinoid, metabolite, and terpene blood levels, and 100+ endocannabinoids and related lipid mediators in approximately 2000 participants.

项目摘要/摘要 落基山大麻研究中心（RM-CRC） 美国最近经历了法律地位和公众接受的巨大变化 大麻。含有不同数量的四氢大麻酚的娱乐和医用大麻产品 （THC）和大麻二醇（CBD）现在在整个北美都广泛使用。尽管有这些变化， 关于THC和CBD影响的研究一直缺乏。这个研究中心的核心目标 卓越的应用是在三个跨越新兴，中年和年龄较大的研究项目中评估 成人，CBD如何影响对THC的使用和主观反应，以及这些影响是否是由 内源性大麻素系统（ECS）和相关脂质。为此，三个研究项目 RM-CRC利用研究策略来利用三项关键创新。首先，这些项目将采用手机 药理学实验室收集生物样品并评估THC和CBD对密钥的急性影响 神经认知和行为结果，内源性大麻素和其他与EC相互作用的脂质。第二， 在我们为大麻衍生的CBD持有的FDA IND的主持下，项目将随机分配参与者 CBD或安慰剂，并将参数处理CBD的剂量或CBD产品是否包含 THC，确定大麻衍生的CBD产品如何影响THC的影响。最后，项目依靠 我们的大麻研究分析核心（CRAC）中新设计的测定法，以测量大麻素， 血液样本中的代谢物，萜烯，内源性大麻素和其他脂质介质。数据协调 和分析核心（DHAC）将部署一个单一解决系统来支持数据收集，跨越协调 直接和通过NIH批准的存储库与大型科学界共享项目，并共享数据。 DHAC还将协调先前收集的数据（从7个R01，n = 1359）并进行高级机器 对THC和CBD血液水平，内源性大麻素和其他脂质之间关系的学习分析 调解人和行为数据。结果将为统一P50项目数据的中心分析提供信息。 因此，CRAC和DHAC为RM-CRC提供了显着的附加值，这将使中心得以实现 关于EC和相关脂质的变化如何介导的重要新知识 THC和CBD在整个寿命中的影响。 RM-CRC有望成为该领域的重要资源 更广泛地通过为其他科学家访问有关CBD对精神病和健康的影响的数据而更广泛地 结果，大麻素，代谢产物和萜烯血液水平以及100多个内源性大麻素和相关脂质 大约2000名参与者的调解人。